Wojciech Szczepanik, PhD, MBA, joins FutureMeds as the Executive Vice President of Site Operations. This strategic appointment marks a significant step in FutureMeds’ commitment to enhancing operations, boosting client benefits and expanding the site network’s impact in clinical trials.
Wojciech Szczepanik, an experienced professional, joins FutureMeds as the Executive Vice President of Site Operations to enhance operations and support the organisation in evolving its site and DCT solutions. He will be working closely with the leadership and site teams.
"Wojtek is an exceptional operator in the Site space, and his decision to join FutureMeds will be a key factor in our growth. He is an excellent team leader, and I am confident that his positive attitude and clinical research expertise will greatly benefit our sites, patients and clients. I am thrilled working with Wojtek on my side."
— Dr Radoslaw Janiak, CEO at FutureMeds
Wojciech brings a wealth of experience to the table. His journey in the clinical trials landscape began with a PhD in biomedicinal chemistry and lecturing at the University of Wroclaw, followed by pivotal roles at renowned organisations in clinical research.
His career highlights include close to 4 years as a monitor at AstraZeneca in the fields of cardiology, pulmonology, and oncology. After AstraZeneca, he joined Synexus as a Site Director. Over 11 years, and in various senior operational roles, he helped the organisation become the biggest site network and supported the company in navigating the Accelerated Enrollment Solutions (AES) acquisition process.
He left AES as Head of EMEA Sites in 2019 to support the growth of Pratia, a prominent site network, through mergers and acquisitions as the Vice President of the International Site Network.
Wojciech’s appointment comes at a crucial time for FutureMeds. The site network has entered a new growth phase and seeks to extend into new geographical regions and therapeutic indications.
Under Wojciech’s leadership, FutureMeds is poised to see enhanced operational efficiency across its site network. His expertise in strategic planning, resource management, and risk mitigation will ensure more streamlined operations, fostering a skilled and motivated workforce.
His vision for expanding into new territories and indications will not only benefit the organisation internally but also enhance patient access to new treatments and increase the value of services provided to clients.
His personal commitment to clinical research as a means to combat diseases and improve human lives aligns perfectly with FutureMeds’ mission of conducting efficient and dedicated research.
“Clinical research is one of the most important and exciting fields as it enables us to discover new ways of combating diseases that continue to affect humankind, providing us with the opportunity to live longer and happier lives. Futuremeds conducts clinical trials with high efficiency in our dedicated facilities, with readiness for dynamically changing trends and with the great commitment of our teams.”
— Wojciech Szczepanik, EVP of Site Operations
Wojciech’s appointment is a clear indicator of FutureMeds’ dedication to increasing its experienced site teams’ impact in clinical research. With his guidance, FutureMeds is set to speed up growth, solidifying its position at the forefront of clinical research and continuing its mission to bring life-changing therapies to those in need.
Specialising in conducting clinical trials, FutureMeds is the 1st European Independent Dedicated DCT Site Network offering high levels of traditional and Decentralised Clinical Trial capabilities across the whole network and home nursing solutions in 18 European countries.
FutureMeds is driven by a purpose to connect a global healthcare community and help bring quicker access to life-changing medications and therapies to all those who need them worldwide.
FutureMeds’ Dedicated Research Site (DRS) teams serve as the company’s service foundation. DRS team’s capabilities help pharmaceutical companies and contract research organisations accelerate study timelines, streamline processes, lower costs, improve data quality and ultimately help speed up drug development and patient access to new treatments.
FutureMeds @home, the company’s Decentralised Clinical Trial solution, provides pharmaceutical companies, contract research organisations and other partners with powerful insights, tools, teams & support, enabling them to simplify patient access to trials and boost recruitment, engagement and retention.
Through its acquisitions, partnerships and a strategic focus on patient experience, FutureMeds brings opportunities to diverse European patient populations to participate in clinical research under the medical supervision of qualified physicians and health care professionals.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.